Skip to content

Evaluating the Safety and Efficacy of Mussel Adhesive Proteins in Wound Healing of Atrophic Acne Scar after Treatment of Ultra-Pulsed Fractional CO2 Laser: A Split-face Study

Evaluating the Safety and Efficacy of Mussel Adhesive Proteins in Wound Healing of Atrophic Acne Scar after Treatment of Ultra-Pulsed Fractional CO2 Laser: A Split-face Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073529
Enrollment
Unknown
Registered
2023-07-13
Start date
2023-07-15
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Acne Scar

Interventions

Test side:Mussel Adhesive Proteins
Control side:Desonide cream twice a day (3 days in total), fusidic acid cream twice a day (7 days in total), and recombinant human epidermal growth factor four times a day (7 days in total).

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, gender is not limited; 2. Meet the diagnosis of facial atrophic acne scars, and the severity of acne scars on both sides of the face is consistent; 3. The course of the disease is more than 3 months; 4. Those who can persist in completing the treatment and follow-up and have not used other methods of treatment during the period; 5. Subjects participate voluntarily and need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. People with photosensitive skin or those who used photosensitive drugs within 4 weeks; 2. Those who have received sun exposure in the past 1 month or may receive sun exposure 1 month after treatment; 3. Those who have used retinoic acid drugs in the past 1 month; 4. There is skin infection at the treatment site, or there are wounds or incisions that have not healed; 5. People with scar constitution; 6. Pregnant or lactating patients; 7. Patients with heart, kidney, liver insufficiency or other serious underlying diseases; 8. Patients with immunodeficiency diseases; 9. Patients with mental illness; 10. Those with unrealistic expectations.

Design outcomes

Primary

MeasureTime frame
VISIA image analysis;transepidermal waterloss, TEWL;Water content of Stratum corneum;Sebum measurement;Skin melanin index;

Secondary

MeasureTime frame
Erythema, edema, degree of pigmentation;comfort evaluation;Scab removal time;

Countries

China

Contacts

Public ContactYan Wu

The First Hospital of China Medical University

jlwuyan@126.com+86 24 8328 2116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026